First to Market, First in Market Share: Timing is Key!
The timing of a therapy’s market entry significantly influences the share it captures, highlighting the competitive advantage of being first. For example, with only two competing drugs, the first entrant secures nearly 60% of the market, leaving just over 40% for the second. This gap broadens further as additional competitors enter, ultimately translating into a higher Return on Investment (ROI) for first movers.
Source: International Journal of Pharmaceutical and Healthcare Marketing Vol. 2 No. 1, 2008
Read the article (subscription required)
1st entrant
2nd entrant
4th entrant
100%
58%
42%
43%
31%
26%
35%
25%
21%
19%
30%
22%
18%
14%
16%
5th entrant
3rd entrant
Accelerate Process Development Timelines
Leveraging our platform and specialized expertise, MaxCyte has a proven track record of helping customers reduce process development timelines by as much as four months, saving an estimated $4M in cash burn and accelerating path to the clinic. Our dedicated support teams ensure smooth integration, optimizing your workflows for scalable, reproducible outcomes.
With Kamau Therapeutics, we supported pre-clinical scale-up and optimization in under three months, accelerating IND filing and funding milestones.
Learn more about accelerating process development timelines
Concept Discovery
Optimization – Early PD
Without MaxCyte
With
Streamline Clinical Development and Reduce Regulatory Risk
Gain access to our robust FDA Master File and customized technical files, which have supported over 70 cell therapy clinical trials globally. Our customers have completed successful fillings with agencies in several countries including the United States, Canada, Australia, Switzerland, the United Kingdom, Austria, Belgium, France, Germany, Italy, Netherlands, Spain, Japan, and Singapore.
Learn more about MaxCyte's regulatory support
Comprehensive Support Throughout Development
Leverage our unmatched scientific and technical support throughout your entire development journey. Enjoy lifetime support throughout the product life cycle, including scale-up and scale-out at all manufacturing sites, and benefit from 24/7 support during commercial manufacturing runs.
Immunology
iPSC and stem cells
Process development
Cell-based assays
Gene editing
Mammalian Cell Transfection
Viral vectors and vaccines
Cumulative Experience (Years) of Our Scientists in Key Fields
52
52
75
35
45
45
82
Learn more about our Scientific & Technical Support
A Proven GMP-Ready Process for Scalable T Cell Engineering
MaxCyte’s Flow Electroporation® technology provides a cGMP-compatible approach for efficient, non-viral engineering of T cells at clinical scale. This process enables high-efficiency transgene integration while maintaining cell viability, accelerating the development of next-generation cell therapies.
The KSQ case study illustrates how MaxCyte platforms enabled the development of a scalable, GMP-compliant process, achieving >90% gene-editing efficiency and ensuring seamless tech transfer to support IND clearance.
Learn more about GMP-ready scalability from day one
Flexible Technology for Any Development Need
MaxCyte’s electroporation technology is compatible with a wide range of cargos, cell types, and sources—both autologous and allogeneic—making it ideal for diverse clinical applications. Active clinical trials with HSCs, T-cells, PBMCs, TILs, B-cells, and NK-cells highlight its unmatched versatility.
Autologous
Allogeneic
T-cells
HSCs
TILs
NK-cells
PBMCs
Monocytes
Dendritic Cells
B Cells
Explore the diverse cell types and cargos engineered with MaxCyte
Clinically and Commercially Proven Platform
MaxCyte's platform has enabled more than 70 clinical trials and has been successfully tech-transferred to 40+ CDMO sites in over eight countries.
Hear from one of our FAS about supporting clinical manufacturing success across multiple sites.
Used in the manufacturing of Vertex Pharmaceuticals and CRISPR Therapeutics’ groundbreaking CRISPR/Cas9 gene-edited cell therapy, CASGEVY®.
Learn more
Increased Return on Investment (ROI)
Speed to Clinic
Regulatory Strength
On-demand Support
Scalable GMP Process
Flexible Technology
Clinical & Commercial Success
25
18
15
1
4
2
2
2
2
1
Harvest cells from healthy donor
T Cell activation
Day 0
MaxCyte Electroporation
Day 2
CAR T Cell expansion
Day 7–10
Cellular characterization
Day 7–10
Cas9 RNP
Cas9 RNP
Flow cytometry
CTS
Left homology
Right homology
CTS
Insert
MaxCyte enables seamless transition from research to GMP-compliant manufacturing on a single platform, saving months in development. This approach maintains an optimal product biology, facilitates early proof-of-concept, and accelerates the time to clinic.
A Proven GMP Scalable Process from the Get-Go